{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '23', 'Version Date: 07/22/2019', 'Dose Level', 'Dose reduction (mg/m\u00b2/dose)', 'Dose reduction (%)', 'Dose 1', '30mg/m\u00b2/dose', '~30%', 'Dose -2', '20mg/m\u00b2/dose', '~30%', '5.4 QUESTIONNAIRES (APPENDIX III AND APPENDIX IV)', 'The pediatric PROMIS instruments and the Distress Rating Tool will be administered to all', 'consenting patients who speak English or Spanish with parallel Parent Proxy instruments', 'administered to parents of patients ages 12-17. These instruments will be administered at', 'baseline, at the end of cycle 4 and every 4 cycles thereafter, and at the time a patient is taken', 'off treatment (see Section 5.7). Since the measures have not been validated in other', 'languages, participation in this portion of the study will be limited to subjects who speak', 'either English or Spanish.', '5.4.1 PROMIS', 'The Patient-Reported Outcome Measurement Information System (PROMIS), funded by', 'the National Institutes of Health to provides clinicians and researchers access to efficient,', 'precise, valid, and responsive parent- and child-reported measures of health and well-being.', '5.4.2 Distress Rating Tool', 'All patients ages 12 years or older will complete the Distress Thermometer. The Distress', 'Thermometer takes less than 5 minutes to complete.', '5.5 ON-STUDY EVALUATION', '5.5.1 Baseline Assessment', 'Laboratory values must be no older than 72 hours from the time of eligibility evaluation and', 'starting therapy. Imaging studies must be no older than 4 weeks of enrollment at enrollment.', 'Testing outside of this window must be repeated prior to starting study drug.', 'If a post-enrollment/pre-treatment laboratory value is outside of the limits of eligibility, this', 'laboratory value must return to the eligibility requirement prior to initiating therapy. If the', 'laboratory value does not return to the limits of eligibility within 14 days, patient may not', 'receive protocol therapy.', 'The evaluations required prior to starting treatment portion of the study are listed in Section', '5.6, Study Calendar. Screening labs will be repeated if they are older than 72 hours.']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '24', 'Version Date: 07/22/2019', '5.6 STUDY CALENDAR', 'Post Therapy', 'Follow-up', '(approximately', '30 days after', 'Subsequent Cycles (', 'final dose of', 'Cycle 1 (I 3 days)', '3 days)', 'study drug)', 'Day 2-', 'Day', 'Procedure', 'Screening', 'Baseline', 'Day 1', '5', 'Day 7', '14', 'Day 28', 'Day 1-5', 'Day 28', 'History', 'X', 'X', 'Physical Exam', 'X', 'Xa', 'X', 'Vital signs', 'X', 'X', 'Xi', 'X', 'Performance Score', 'X', 'Xa', 'SGI-110 Administration', 'X', 'X', 'X', 'Labs', 'Complete blood countwith', 'diff, platelets', 'Electrolytes (including', 'sodium, potassium,', 'chloride, CO2), calcium,', 'X', 'Xa', 'X', 'phosphorus, magnesium,', 'creatinine, BUN, glucose,', 'ALT, bilirubin, urinalysis,', 'total protein, albumin, and', 'CPK', 'Serum normetanephrine', 'and metanephrine (if', 'possible, urine), and', 'X', 'Xi', 'chromogranin A (in', 'patients with PHEO/PGL', 'only)']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '25', 'Version Date: 07/22/2019', 'Post Therapy', 'Follow-up', '(approximately', '30 days after', 'Subsequent Cycles (', 'final dose of', 'Cycle 1 (I 3 days)', '3 days)', 'study drug)', 'Day 2-', 'Day', 'Procedure', 'Screening', 'Baseline', 'Day 1', '5', 'Day 7', '14', 'Day 28', 'Day 1-5', 'Day 28', 'Urine/serum pregnancy test', 'for all females of', 'X', 'Xk', 'childbearing potential', 'Biopsies', 'Xc', 'Xg', '1) Tumorexpression ofSDH', 'complex subunits and FH', 'X', 'Xg', 'by IHC', '2) Tumorexpression of NY-', 'Xf', 'Xg', 'ESO-1 by IHC', 'LINE-1 demethylation', 'analysis (Dr. Meltzer', 'X', 'X', 'research)', 'Pharmacokinetic testing', 'X', 'Xd', 'Xd', 'Pharmacodynamic testinge', 'X', 'X', 'X', 'X', 'Response evaluation of', 'X', 'Xb', 'Xb', 'disease b', 'Quality of Life (Distress', 'X', 'Xh', 'Xh', 'thermometerand PROMIS)', 'Adverse Events', 'X', 'X', 'Concomitant Medications', 'X', 'X', 'a', 'Laboratory tests older than 2 weeks (14 days) at the start of therapy must be repeated. For abnormal test results,', 'refer', 'to', 'Section', '4.2.', 'b Imaging studies will be repeated if older than 4 weeks at the start of therapy. Imaging evaluation selection may include CT and/or MRI, and/or FDG-PET', 'as clinically indicated. Staging should be performed prior to the second cycle and then prior to every other cycle. The same imaging strategy will be used', 'throughout study participation for tumor evaluation.']\n\n###\n\n", "completion": "END"}